Video.mp4 (63.63 MB)

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

Download (63.63 MB)
media
posted on 10.12.2018 by Maximilian J. Hochmair, Anna Buder, Sophia Schwab, Otto C. Burghuber, Helmut Prosch, Wolfgang Hilbe, Agnieszka Cseh, Richard Fritz, Martin Filipits

Article full text


The full text of this article can be found here.


Disclosures

Maximilian J. Hochmair has received honoraria from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche and had consulting or advisory roles with Boehringer Ingelheim, Merck Sharp & Dohme, Novartis and Roche. Anna Buder has received honoraria from AstraZeneca. Helmut Prosch has received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, and Roche, and has received a research grant from Boehringer Ingelheim. Wolfgang Hilbe has received advisory board and lecture fees from Boehringer Ingelheim. Agnieszka Cseh and Richard Fritz are employees of Boehringer Ingelheim. Martin Filipits has received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Ratiopharm, and Roche. Sophia Schwab, and Otto C. Burghuber have no conflicts of interest to declare.


Funding

Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Katharine Williams of GeoMed, an Ashfield company, part of UDG Healthcare plc, during the development of this manuscript.


Copyright

This video is distributed under the terms of the Creative Commons Attribution Noncommerical Licence which permits any noncommerical use, distribution, and reproduction in any medium, provided the original author(s) and the source is credited.


Article full text

The full text of this article can be found here.

Funding

Boehringer Ingelheim

History

Licence

Exports

Logo branding

Categories

Licence

Exports